SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending due to a combination of an SEC filing revealing updated change-of-control agreements for senior management, which investors are interpreting as preparation for a potential buyout, and intense short-covering pressure fueled by high borrow fees. The community is actively discussing the stock's positioning ahead of upcoming clinical milestones, with many long-term shareholders expressing conviction in the company's oncology platform while short sellers face significant volatility.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is experiencing intense volatility driven by heavy insider selling, which has fueled widespread community concern about the company's valuation and technical progress. While some bulls remain focused on the potential for government-backed quantum development, many traders are leaning into bearish positions as the stock struggles to maintain support levels amid broader sector de-risking.

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is facing intense community scrutiny and bearish sentiment as the stock decouples from Bitcoin, leading to heated debates over the sustainability of its debt-fueled acquisition model and dividend obligations. Traders are actively monitoring the stock for a potential bottom while weighing risks of further dilution against claims that it represents a generational buying opportunity.

Paramount Skydance Corp. is a next-generation global media and entertainment company that engages in providing content creation and distribution services. It operates through the following business segments: Studios, Direct-to-Consumer, and TV Media. Its portfolio unites brands including Paramount Pictures, Paramount Television, CBS, CBS News, Nickelodeon, MTV, BET, Comedy Central, Showtime, Paramount Plus, Pluto TV, and Skydance’s Animation, Film, Television, Interactive/Games, and Sports divisions. The company is headquartered in New York, NY.

Paramount Skydance Corp. - Ordinary Shares - Class B

Paramount Skydance is trending as it secures critical DOJ clearance for its acquisition of Warner Bros. Discovery, signaling a major milestone for the media conglomerate despite ongoing scrutiny from state attorneys general and international regulators. Community sentiment is heavily focused on the stock's long-term potential following the merger, with many investors debating the impact of integration efforts, regulatory hurdles, and management's strategy to compete with streaming giants.

REalloys, Inc. is engaged in the rebuilding of domestic supply chain resilience for rare earth elements and magnets. It is involved in recycling, mining, oxide production, metallization, alloying, and magnet manufacturing. The company was founded on October 4, 2011 and is headquartered in Boca Raton, FL.

REalloys Inc.

REalloys is gaining significant momentum as investors track its strategic role in building a domestic U.S. supply chain for critical heavy rare earth elements ahead of upcoming defense procurement mandates. The community is heavily focused on the company's recent partnership agreements, pending financing milestones, and potential index inclusion, viewing the stock as a key long-term play against global supply dependencies.

Serve Robotics, Inc. engages in providing self-driving delivery. It designs, develops, and operates zero-emissions robots that serve people in public spaces, starting with food delivery. The company was founded by Ali Kashani, Dmitry Demeshchuk and MJ Burk Chun in 2017 and is headquartered in Redwood City, CA.

Serve Robotics Inc

Serve Robotics is trending due to a combination of strong fourth-quarter financial results, including an revenue guidance raise to $26 million, and a new partnership with White Castle via Uber Eats. The stock's heavy short interest has fueled significant discussion around the potential for a short squeeze as investors weigh these expansion milestones against ongoing debates about the company's valuation and path to profitability.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio Inc. (IBRX) is trending as investors debate the potential catalyst of a Russell 1000 index inclusion, which could trigger passive institutional buying despite ongoing skepticism regarding the company's eligibility due to banding rules. Meanwhile, the community remains intensely focused on the long-term potential of the Anktiva platform and AI-driven developments, while actively tracking institutional activity and short interest to gauge if a squeeze or significant price breakout is imminent.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It operates through the following segments: Uranium, Rare Earth Elements (REE), and Heavy Mineral Sands (HMS). The uranium segment engages in conventional and ISR uranium extraction, recovery and sales of uranium from mineral properties and the recycling of uranium-bearing materials generated by third parties along with the exploration, permitting and evaluation of uranium properties in the U.S. The REE segment is engaged in the company’s initiatives to progress towards full REE separation capabilities at the Mill to produce both light and heavy separated REE oxides in the coming years. The HMS segment engages in the exploration, development and recovery of HMS at the Kwale Project, Bahia Project, Vara Mada Project and the company’s equity method investments in the Donald Project JV and Tate. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels Inc. is trending as investors weigh significant government loan commitments and a transformational acquisition against recent price volatility and sector-wide weakness. The community remains deeply divided, with bulls pointing to the company's strategic role in securing the domestic uranium and rare earth supply chain, while detractors express frustration over recent price declines and concerns regarding dilution.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Eos Energy Enterprises is trending as investors react to positive analyst coverage and a recent operational expansion involving its Pennsylvania manufacturing facility. The community is actively discussing the company's long-term potential within the AI-driven grid infrastructure sector, while weighing the impact of continued share dilution against the momentum from new purchase orders and strategic partnerships.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is currently trending as investors weigh conflicting signals from ongoing geopolitical tensions in the Middle East and the upcoming transition to Fed Chair Kevin Warsh. The community is actively debating the potential for rate hikes, with many traders closely monitoring long-term bond yields and inflation expectations as the primary drivers for price direction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

DecisionDx-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy

DecisionDx-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy DecisionDx-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy PR Newswire FRIENDSWOOD, Texas, June 25...

Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal

Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal PR Newswire FRIENDSWOOD, Texas, June 23, 2026 Stokes was...

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire FRIENDSWOOD, Texas, June 19, 2026 FRIENDSWOOD, Texas, June 19, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq...

Castle Biosciences' TissueCypher Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus

Castle Biosciences' TissueCypher Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus Castle Biosciences' TissueCypher Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus PR Newswire...

Castle Biosciences' AdvanceAD-Tx Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation

Castle Biosciences' AdvanceAD-Tx Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation Castle Biosciences' AdvanceAD-Tx Test Receives 2026 MedTech Breakthrough Award for Genomics...

Castle Biosciences (NASDAQ:CSTL) Releases Earnings Results, Hits Expectations

Castle Biosciences (NASDAQ:CSTL - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.49) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.49). The company had revenue of $84.23 million during the quarter, compared to analysts...

Castle Biosciences Q1 Earnings Call Highlights

Castle Biosciences (NASDAQ:CSTL) reported first-quarter 2026 revenue of $83.7 million, supported by continued growth in what management described as its "core revenue drivers," DecisionDx-Melanoma and TissueCypher. Founder, President and CEO Derek Maetzold said test report volumes for the company's...

Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Beats Revenue Estimates

Castle Biosciences (CSTL) delivered earnings and revenue surprises of +12.50% and +2.65%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Castle Biosciences Reports First Quarter 2026 Results

Castle Biosciences Reports First Quarter 2026 Results Castle Biosciences Reports First Quarter 2026 Results PR Newswire FRIENDSWOOD, Texas, May 6, 2026 Delivered Q1 2026 revenue of $83.7 millionQ1...

Alkermes' Q1 Earnings & Revenues Beat Estimates, Stock Rises

ALKS beats Q1 estimates as strong proprietary drug sales lift revenues by 28%, sending shares higher, while Lumryz adds a fresh growth driver.

Castle Biosciences, Inc.is a molecular diagnostics company offering innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, barrett’s esophagus, uveal melanoma, and in the treatment of mental health conditions. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.

Castle Biosciences Inc

Neutral Sentiment

$UBER only

$INTC only

Both $UBER and $INTC

Neither

Nancy Pelosi recently disclosed trades in both Uber ($UBER) and Intel ($INTC) - are you following her into either? Cast your vote below.

Are you following Nancy Pelosi into her latest trades - Uber ($UBER) and Intel ($INTC)?

Feed

News

Sentiment

Earnings

Fundamentals

Info

CSTLCastle Biosciences Inc

Fundamentals

Latest CSTL News